CXCR4 and hematopoietic and lymphoid system neoplasm: Recently, beta emitter labeled analogs of CXCR4-ligands ([177Lu]/[90Y] Pentixather) have been tested as a novel therapeutic approach in patients with hematological neoplasm (i.e. multiple myeloma).